3 Stocks That Could Climb Higher: GH Research (GHRS), Nutex Health (NUTX), Cardiol Therapeutics (CRDL)

Across biotechnology and healthcare markets, investor sentiment is closely influenced by the pace and significance of clinical milestones achieved by emerging therapies. While short-term volatility is not uncommon, sustained market interest is often centered on solutions that address critical gaps in current standards of care.

GH Research PLC (GHRS)

GH Research PLC (NASDAQ: GHRS) opened trading on May 12, 2026, with great promise as it jumped 1.32% to $21.54. During the day, the stock rose to $21.75 and sank to $20.89. Taking a long-term approach, GHRS posted a 52-week range of $9.46-$24.66.

The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 162.03%. Meanwhile, its Annual Earnings per share during the time were -162.03%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is -84.53%. This publicly-traded company’s shares outstanding now amount to $62.03 million, simultaneously with a float of $49.37 million. The organization now has a market capitalization of $1.48 billion.

Nutex Health Inc (NUTX)

Nutex Health Inc (NASDAQ: NUTX) started the day on May 12, 2026, with a price increase of 1.96% at $135.48. During the day, the stock rose to $135.53 and sank to $128.01. Taking a long-term approach, NUTX posted a 52-week range of $77.21-$193.07.

Nevertheless, the stock’s Earnings Per Share (EPS) this year is 100.57%. This publicly-traded company’s shares outstanding now amount to $6.95 million, simultaneously with a float of $4.74 million. The organization now has a market capitalization of $932.28 million. Its Quick Ratio in the last reported quarter now stands at 3.12.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is advancing a broader cardiovascular growth strategy through the development of next-generation therapies aimed at large and underserved markets. By expanding beyond recurrent pericarditis, the company is positioning itself to participate in areas where inflammation and fibrosis remain important drivers of disease progression.

Market Momentum

As of May 12, 2026, CRDL closed at $1.35, up 1.12%, with trading volume of 353,515 shares compared to an average volume of 689,450 shares. The company currently maintains a market capitalization of $150.768M and a beta of 0.43, reflecting relatively moderate volatility compared to many small-cap biotech peers. Shares continue to trade within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.39 suggests substantial upside potential tied to pipeline advancement and future clinical milestones.

Pipeline Development: CRD-38

Cardiol is developing CRD-38, a proprietary subcutaneous therapy designed to improve dosing convenience while expanding applicability into broader cardiovascular indications, including heart failure. The therapy is intended to target inflammation and fibrosis, two biological mechanisms strongly associated with declining cardiac function and progressive heart disease.

Market Opportunity

Heart failure represents one of the largest cardiovascular markets globally, affecting millions of patients and generating significant healthcare costs annually. Despite multiple treatment options already available, unmet need remains for therapies capable of directly addressing inflammatory and fibrotic pathways that contribute to disease progression.

Outlook

As CRD-38 advances toward future clinical development, the program could emerge as an important secondary value driver for Cardiol. Continued progress across the company’s pipeline may strengthen its long-term positioning within the cardiovascular biotechnology sector.